Annexon reports Q2 EPS (34c), consensus (36c)

Cash and cash equivalents and short-term investments were $227M as of June 30. “We are well positioned to achieve our mission of helping millions of people with devastating complement-mediated diseases live their best lives by the consistent validation generated by our innovative C1 platform across multiple potential best-in-class therapeutics,” said Douglas Love, president and chief executive officer of Annexon (ANNX). “In Guillain-Barre Syndrome, approximately 90% of tanruprubart-treated patients improved by week 1 and more than twice as many patients achieved a normal state of health at week 26 vs. placebo in our Phase 3 study. As a result, we are actively engaged in global regulatory interactions to bring tanruprubart to patients worldwide, which includes preparing to submit our Marketing Authorization Application to the European Medicines Agency in the first quarter of 2026. In parallel, we are also working with the Food and Drug Administration to gain clarity on the generalizability package to support a Biologics License Application submission.”